Horizon Europe's Cluster 1 (Health) funds collaborative European projects to improve health, healthcare systems, and biomedical innovation. Below are the 2026 calls open until 13 April 2027.

·  Destination 1: Staying healthy in a rapidly changing society

• HORIZON-HLTH-2027-01-STAYHLTH-01: Addressing disabilities through the life course to support independent living and inclusion

·  Destination 2: Living and working in a health-promoting environment

• HORIZON-HLTH-2027-01-ENVHLTH-02: Integrating climate-related exposures into the human exposome and characterising its changes in response to climate change
• HORIZON-HLTH-2027-01-ENVHLTH-MISSCLIMA-03: Tools and technologies to support health adaptation to climate change

·  Destination 3: Tackling diseases and reducing disease burden

• HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
• HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
• HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
• HORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
• HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials
• HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
• HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative diseases

·  Destination 4: Ensuring equal access to innovative, sustainable, and high-quality healthcare

• HORIZON-HLTH-2026-04-CARE-04: Enhancing and enlarging the European Partnership on Personalised Medicine (EP PerMEd) (Top-up)
• HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications

·  Destination 5: Developing and using new tools, technologies and digital solutions for a healthy society

• HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
• HORIZON-HLTH-2027-03-TOOL-02: Advancing bio-printing of living cells for regenerative medicine
• HORIZON-HLTH-2027-03-TOOL-04: Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
• HORIZON-HLTH-2027-03-TOOL-08: Towards Artificial General Intelligence (AGI) for healthcare

·  Destination 6: Maintaining an innovative, sustainable, and competitive EU health industry

• HORIZON-HLTH-2027-01-IND-01: Development of cell-free protein synthesis platforms for discovery and/or production of biologicals
• HORIZON-HLTH-2027-02-IND-02-two-stage: Portable and versatile Point-of-care diagnostics

• Open to any legal entity established in an EU Member State or an associated country, including research organizations, universities, hospitals, and industry partners.

• Research and Innovation Actions (RIA) and Innovation Actions (IA): transnational consortia required, composed of at least one legal entity established in an EU Member State and at least two additional entities from EU Member States or associated countries.

• Coordination and Support Actions (CSA): participation of one or more entities established in EU Member States or associated countries.

• Public Procurement of Innovative Solutions (PPI): transnational consortia required, composed of at least one legal entity established in an EU Member State and at least two entities from EU Member States or associated countries; at least two partners must be public buyers subject to public procurement rules, including one from an EU Member State and one from an EU Member State or an associated country.

• Specific eligibility criteria may vary by topic; please consult the official work programme for details.

In case of interest, please click on 'm'interessa' and we will contact you.